Our approach allows us to streamline the discovery and development process.
Ventyx is a clinical-stage biopharmaceutical company focused on advancing novel oral therapies for patients living with autoimmune and inflammatory disorders. Our pipeline includes VTX958, a Phase 2 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases; VTX002, a Phase 2 S1P1 receptor modulator for the treatment of ulcerative colitis; VTX2735, a Phase 2 peripheral inhibitor of the NLRP3 inflammasome; and VTX3232, a Phase 1 CNS-penetrant inhibitor of the NLRP3 inflammasome.